

1 Todd Benoff (Bar No. 192983)  
2 *Todd.Benoff@alston.com*  
3 **ALSTON & BIRD LLP**  
4 333 South Hope Street, 16th Floor  
5 Los Angeles, CA 90071  
6 Telephone: (213) 576-1000  
7 Facsimile: (213) 576-1100

8 Natalie Clayton  
9 **ALSTON & BIRD LLP**  
10 90 Park Ave., 15th Floor  
11 New York, NY 10016  
12 Telephone: (214) 922-3400  
13 Facsimile: (214) 922-3899

14 *(Additional counsel on signature page)*

15 *Attorneys for Plaintiff Sandoz Inc.*

16  
17  
18 **UNITED STATES DISTRICT COURT**  
19 **CENTRAL DISTRICT OF CALIFORNIA**  
20 **WESTERN DIVISION**

21 **SANDOZ INC.,**

22 **Plaintiff,**

23 **vs.**

24 **AMGEN INC. and**  
25 **AMGEN MANUFACTURING**  
26 **LIMITED,**

27 **Defendants.**

28 **Case No.** \_\_\_\_\_

**COMPLAINT FOR:**

- i. False Advertising (in violation of the Lanham Act, Section 43(a), 15 U.S.C. § 1125 *et seq.*);
- ii. False Advertising (in violation of Cal. Bus. & Prof. Code §§ 17500 *et seq.*);
- iii. Unfair Competition (in violation of Cal. Bus. & Prof. Code §§ 17200 *et seq.*)

**DEMAND FOR JURY TRIAL**

**PRELIMINARY STATEMENT**

1  
2 1. Plaintiff Sandoz Inc. (“Sandoz” or “Plaintiff”) brings this action for false  
3 advertising, by and through its counsel, against Defendants Amgen Inc. and Amgen  
4 Manufacturing Limited (collectively, “Amgen” or “Defendants”).

5 2. Sandoz is a pioneer and global leader in providing affordable biosimilar  
6 products to patients. In particular, Sandoz has devoted significant resources to develop,  
7 manufacture, market and sell a pegfilgrastim prefilled syringe product, sold under the  
8 brand name Ziextenzo®, which is used to reduce the incidence of infections in patients  
9 with cancer receiving chemotherapy.

10 3. The Food and Drug Administration (“FDA”) approved Sandoz’s  
11 Ziextenzo® product as a biosimilar to Amgen’s pegfilgrastim prefilled syringe named  
12 Neulasta®, only for Amgen to taint the marketplace shortly after Sandoz launched its  
13 product.

14 4. Amgen has engaged in a deliberate and audacious marketing campaign that  
15 falsely states that pegfilgrastim prefilled syringe products, which includes Sandoz’s  
16 Ziextenzo® product, are less effective and thus, by implication, less safe as compared  
17 to Amgen’s pegfilgrastim administered through its on-body device, named Neulasta®  
18 Onpro®. Relying on inadequately designed studies—for which Amgen has already  
19 been admonished once by the FDA—Amgen has made false and misleading statements  
20 to the medical and healthcare communities and public representing that its product is  
21 superior in safety and efficacy when it is not.

22 5. Amgen willfully disseminated erroneous scientific conclusions in a bold  
23 effort to undermine Sandoz’s ability to provide patients more affordable medicine,  
24 competing unfairly to the detriment of Sandoz and others. The data do not support  
25 Amgen’s erroneous claims that pegfilgrastim prefilled syringe products, including  
26 Sandoz’s Ziextenzo®, are less effective than Neulasta® Onpro®. Amgen’s  
27 comparative advertising claims are false and misleading.

28 6. Defendants’ actions constitute false advertising in violation of Section

1 43(a)(1)(B) of the Lanham Act, 15 U.S.C. § 1125(a)(1)(B); false advertising in violation  
2 of California False Advertising Law, Cal. Bus. & Prof. Code § 17500 *et seq.*; and unfair  
3 competition in violation of California Unfair Competition Law, Cal. Bus. & Prof. Code  
4 § 17200. Plaintiff seeks permanent injunctive relief, Plaintiff's damages, disgorged  
5 profits, corrective advertising, recovery of Plaintiff's costs and reasonable attorneys'  
6 fees incurred in connection with this action and such other, different, and additional  
7 relief as the Court deems just and proper.

### 8 JURISDICTION AND VENUE

9 7. This Court has subject matter jurisdiction over this dispute pursuant to 28  
10 U.S.C. §§ 1331, 1338 and 15 U.S.C. § 1121(a) because this action arises under the  
11 Lanham Act, 15 U.S.C. §§ 1051, *et seq.*

12 8. This Court has jurisdiction over all state law claims pursuant to 28 U.S.C.  
13 §§ 1367 and 1338(b).

14 9. This Court has personal jurisdiction over Defendants because Defendants  
15 transact business within the State of California, contract to supply goods or services in  
16 the State of California, including but not limited to Neulasta®, have engaged in tortious  
17 acts within the State of California, and have engaged in tortious acts outside the State  
18 of California causing injury within the State. More specifically, Defendants market,  
19 promote, advertise, offer for sale, sell, and/or distribute their products, including  
20 Neulasta®, to customers and/or others throughout the United States, including in the  
21 Central District of California. Upon information and belief, Defendant Amgen  
22 Manufacturing Limited manufactures products, including Neulasta®, for and/or in  
23 coordination with Defendant Amgen, and each Defendant serves the market in this  
24 District. Defendant Amgen Manufacturing Limited's involvement with Neulasta® is  
25 further evidenced by the fact that it was a plaintiff along with Amgen Inc. in the patent  
26 suit brought in federal court in California regarding Sandoz's biosimilar version of  
27 Neulasta®. Defendants have purposefully and voluntarily placed their products,  
28 including Neulasta®, into the stream of commerce with the expectation that they will

1 be purchased by consumers in the Central District of California. Defendant Amgen Inc.  
2 also resides in this District, having a principal place of business at One Amgen Center  
3 Drive, Thousand Oaks, California 91320. As such, Defendants have established  
4 minimum contacts with the forum such that the exercise of jurisdiction over them would  
5 not offend traditional notions of fair play and substantial justice.

6 10. Venue is proper in this district under 28 U.S.C. § 1391(b) because Amgen  
7 Inc. resides in this District and a substantial part of the events and injury giving rise to  
8 Plaintiff's claims has and continues to occur in this District.

### 9 THE PARTIES

10 11. Sandoz Inc. is a corporation organized and existing under the laws of the  
11 State of Delaware, with its principal place of business at 100 College Road West,  
12 Princeton, New Jersey 08540. Sandoz develops, manufactures and sells generic and  
13 biosimilar medicines, providing access to high-quality, affordable medicines to millions  
14 of patients.

15 12. Amgen Inc. is a corporation organized and existing under the laws of the  
16 State of Delaware, with its principal place of business at One Amgen Center Drive,  
17 Thousand Oaks, California 91320.

18 13. Amgen Inc. develops, manufactures, markets and sells medicines  
19 addressing various therapeutic areas throughout the United States, including in this  
20 District.

21 14. Amgen Manufacturing Limited is a corporation organized and existing  
22 under the laws of the Territory of Bermuda with its principal place of business at Road  
23 31 km 24.6, Juncos, Puerto Rico 00777.

24 15. Amgen Manufacturing Limited, a wholly owned subsidiary of Amgen Inc.,  
25 manufactures, markets and sells medicines addressing various therapeutic areas  
26 throughout the United States, including in this District.

27 16. Amgen Inc. controls, directs and supervises the activities of Amgen  
28 Manufacturing Limited, as well as its employees.

1 **GENERAL FACTUAL ALLEGATIONS**

2 **A. Biologics and Regulatory Pathway for Biosimilars**

3 17. The products at issue in this litigation are biologic products. Biologics,  
4 unlike conventional drugs, are isolated from a variety of natural sources: human, animal,  
5 or microorganism.

6 18. To market a new biologic product, a company must submit to the FDA a  
7 biologics license application (“BLA”).

8 19. The Biologics Price Competition and Innovation Act of 2009 (“BPCIA”),  
9 Pub. L. No. 111-148, §§ 7001-7003, 124 Stat. 119, 804-21 (2010) (amending, *inter alia*,  
10 35 U.S.C. § 271 and 42 U.S.C. § 262), created an abbreviated pathway for the approval  
11 of biologics that are biosimilar to an FDA-approved reference biologic product.

12 20. A biosimilar is “highly similar to the reference product notwithstanding  
13 minor differences in clinically inactive components,” and has “no clinically meaningful  
14 differences” from the reference product in terms of “safety, purity, and potency.” 42  
15 U.S.C. § 262(i)(2).

16 21. A biosimilar must have the same route of administration, dosage form,  
17 strength, mechanism of action, and conditions of use as the approved reference product.  
18 42 U.S.C. § 262(k)(2)(A)(i)(II)–(IV).

19 22. Biosimilarity is based on analytical studies; animal studies, including  
20 toxicity assessments; and a clinical study or studies, including assessments of  
21 immunogenicity and pharmacokinetics or pharmacodynamics. 42 U.S.C. §  
22 262(k)(2)(A)(i)(I).

23 23. Biosimilars undergo an extensive regulatory evaluation and approval  
24 process by the FDA to prove they match the quality, safety and efficacy of the reference  
25 product.

26 24. A company seeking approval of a biosimilar must submit to the FDA an  
27 abbreviated BLA (“aBLA”). An aBLA can rely on clinical studies that were performed  
28 by the reference biologic product sponsor.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.